Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01190189




Registration number
NCT01190189
Ethics application status
Date submitted
26/08/2010
Date registered
27/08/2010
Date last updated
19/06/2019

Titles & IDs
Public title
Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
Scientific title
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the Primary NCT00294047 Study
Secondary ID [1] 0 0
113621
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Infections, Papillomavirus 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - GSK580299 (Cervarix)

Experimental: Cervarix Group - Healthy female subjects who received control vaccine in the primary study HPV-015 (NCT00294047), were administered three doses of Cervarix vaccine intramuscularly, according to a 0,1,6-month schedule.


Other interventions: GSK580299 (Cervarix)
3-dose schedule intramuscularly vaccination
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Subjects Reporting Any, Grade 3 and Related Serious Adverse Events (SAEs)
Timepoint [1] 0 0
During the entire study period (from Day 0 up to Month 12)
Primary outcome [2] 0 0
Number of Subjects Reporting Any, Grade 3 and Related Medically Significant Conditions (MSCs)
Timepoint [2] 0 0
During the entire study period (from Day 0 up to Month 12)
Primary outcome [3] 0 0
Number of Subjects Reporting Any, Grade 3 and Related Potentially Immune-Mediated Diseases (pIMDs)
Timepoint [3] 0 0
During the entire study period (from Day 0 up to Month 12)
Primary outcome [4] 0 0
Number of Subjects Reporting Pregnancies and Outcomes of the Reported Pregnancies
Timepoint [4] 0 0
During the entire study period (from Day 0 up to Month 12)

Eligibility
Key inclusion criteria
- Subjects who the investigator believes can and will comply with the requirements of
the protocol

- A subject previously enrolled in study NCT00294047, who received the control vaccine,
and who cannot receive the GSK580299 vaccine because the subject is above the age for
which the vaccine is licensed.

- Written informed consent obtained from the subject

- Free of obvious health problems as established by medical history and clinical
examination before entering into the study.

- Female subjects of non-childbearing potential may be enrolled in the study.

- Female subjects of childbearing potential may be enrolled in the study, if the
subject:

- has practiced adequate contraception for 30 days prior to vaccination, and

- has a negative pregnancy test on the day of vaccination, and

- has agreed to continue adequate contraception during the entire treatment period
and for 2 months after completion of the vaccination series.
Minimum age
26 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- Pregnant or breastfeeding.

- A women planning to become pregnant, likely to become pregnant or planning to
discontinue contraceptive precautions during the vaccination phase of the study, i.e.
up to two months after the last vaccine dose.

- Use of any investigational or non-registered product other than the study vaccine
within 30 days preceding the first dose of study vaccine, or planned use during the
study period.

- Previous vaccination against HPV or planned administration of another HPV vaccine
during the study other than that foreseen in the protocol.

- Chronic administration of immunosuppressants or other immune-modifying drugs within
six months prior to the first vaccine dose. For corticosteroids, this will mean
prednisone greater than or equal to 20 mg/day, or equivalent. Inhaled and topical
steroids are allowed

- Planned administration/administration of a vaccine not foreseen by the study protocol
within 30 days (i.e., Day 0-29) of each dose of vaccine, with the exception of
administration of routine meningococcal, hepatitis B, hepatitis A, inactivated
influenza, diphtheria/tetanus and/or diphtheria/tetanus-containing vaccine up to 8
days before each dose of study vaccine. Enrolment will be deferred until the subject
is outside of specified window.

- Concurrently participating in another clinical study, at any time during the study
period, in which the subject has been or will be exposed to an investigational or a
non-investigational product.

NOTE: Subjects enrolled in this study may also be eligible for a four-year gynaecological
follow-up of the HPV-015 study, in which no investigational product will be administered.
Subjects will be invited to the gynaecological follow-up study if either of the following
applies:

- if they test positive for oncogenic HPV infection, but display normal cervical
cytology at their concluding HPV-015 study end visit;

- if they are pregnant so that no cervical sample can be taken at their concluding
HPV-015 study end visit;

- Previous administration of any components of the vaccine.

- Any confirmed or suspected immunosuppressive or immunodeficient condition, based
on medical history and physical examination.

- Cancer or autoimmune disease under treatment.

- Administration of immunoglobulins and/or any blood products within the 3 months
preceding the first dose of study vaccine or planned administration during the
study period.

- History of any reaction or hypersensitivity likely to be exacerbated by any
component of the vaccine

- History of any neurological disorders or seizures.

- Acute disease and/or fever at the time of enrolment.

- Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or
renal functional abnormality, as determined by physical examination or laboratory
screening tests.

Study design
Purpose of the study
Prevention
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/04/2011
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
23/11/2017
Sample size
Target
Accrual to date
Final
137
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Colorado
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Iowa
Country [5] 0 0
United States of America
State/province [5] 0 0
Kansas
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Nebraska
Country [8] 0 0
United States of America
State/province [8] 0 0
New Hampshire
Country [9] 0 0
United States of America
State/province [9] 0 0
North Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Pennsylvania
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Utah
Country [14] 0 0
United States of America
State/province [14] 0 0
Washington
Country [15] 0 0
Canada
State/province [15] 0 0
Alberta
Country [16] 0 0
Canada
State/province [16] 0 0
British Columbia
Country [17] 0 0
Canada
State/province [17] 0 0
Nova Scotia
Country [18] 0 0
Canada
State/province [18] 0 0
Ontario
Country [19] 0 0
Canada
State/province [19] 0 0
Quebec

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This extension study is designed to assess the safety of GSK Biological's human
papillomavirus (HPV) vaccine GSK580299 in female subjects who took part in the primary study
NCT00294047 and received the control vaccine in countries for which the licensed GSK HPV
vaccine is not indicated for the subject's age group (26 years and older). This study is thus
conducted to enable all women who received the control placebo in the primary NCT00294047
study to receive the GSK580299 vaccine.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01190189
Trial related presentations / publications
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01190189